Antihistamine switch
This article was originally published in The Tan Sheet
Executive Summary
CDER expects to reach decision by year-end on whether to switch Rx low- and non-sedating antihistamines Claritin (Schering-Plough), Allegra (Aventis) and Zyrtec (Pfizer) without sponsor consent. In May, FDA's Nonprescription and Pulmonary-Allergy Drugs Advisory Committees found the drugs safe for use in an OTC setting. Issues related to sedation warnings on currently available OTC antihistamines were discussed at a joint FDA/NTSB meeting Nov. 14-15 (1"The Tan Sheet" Nov. 19, p. 3)...
You may also be interested in...
Sedating Drug “Operating Machinery” Warnings Need Clarification – FDAer
Label statements advising "use caution when operating machinery" do not adequately communicate the risks consumers face from potentially sedating or impairing drugs, an FDA rep said Nov. 15
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.